| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
The clinical efficacy mediated by gene-modified CD8+ T-lymphocytes using leukemia antigen-specific T-cell receptor (TCR) gene transfer (artificial cytotoxic T lymphocytes: artificial CTL) depends on the in vivo persistence of those artificial CTL after recognition of leukemia cells. In this study, to this end, we assessed the helper function mediated by newly gene-modified CD4+ T-lymphocytes (artificial helper T cells) using the identical HLA class I-restricted TCR gene which was employed for artificial CTLs. In results, those artificial helper T cells successfully stimulated artificial CTLs to survive longer after recognition of leukemia cells in vivo through the facilitation of memory T-cell formation mediated by artificial CTL.
|
